Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease

Table 1 Sodium-glucose co-transporter inhibitors and their use in non-alcoholic fatty liver disease

SGLT2 inhibitor	ALT	AST	GGT	Bilirubin	BMI	Steatosis	Inflam-mation	Fibrosis	HCC	Adverse effects	Study organism	Ref.
Canagli-flozin	↓	↓	↓	↑	↓	↓	↓	↓	↓	Urogenital tract fungal infections, DKA, amputat-ions, bone fractures	Human	[44,46,76]
Ipraglif-lozin	↓	-	-	NR	↓	↓	↓	↓	NR	Urinary tract infections	Human/Mouse	[49,51]
Dapagli-flozin	↓	↓	↓	NR	↓	↓	↓	NR	NR	Urogenital tract infections, bladder cancer, DKA, amputat-ions	Human	[59,61,76,81]
Empagl-iflozin	↓	-	-	-	↓	↓	↓	↓	NR	Genital tract infections, DKA	Human/Mouse	[62-64]
Remogl-iflozin	↓	↓	NR	NR	↓	↓	↓	NR	NR	Urogenital tract fungal infections	Mouse	[65]
Luseogl-iflozin	↓ or -	↓	↓	NR	↓	↓	↓	↓ or -	NR	Vaginal itching, dehydra-tion	Human/Mouse	[66-68]

SGLT2: Sodium-glucose co-transporter 2; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyltransferase; BMI: Body mass index; HCC: Hepatocellular carcinoma; DKA: Diabetic ketoacidosis; NR: Not reported; ↓: Decreases; ↑: Increases; -: No change.